|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK2 and CCNE1 were increased in carcinomas showing that these use the opposite way to control RB1.
|
26008974 |
2015 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Six of nine carcinomas displaying microsatellite alterations also demonstrated LOH at CDKN2, which may be associated with widespread genomic instability.
|
9764589 |
1998 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.
|
9072554 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas.
|
9815578 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas.
|
8621247 |
1996 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that abnormal regulation of CDK2/cyclins and CDK inhibitors might be involved in deregulated growth of gastric carcinomas.
|
8797888 |
1996 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that, although p16/CDKN2 may play a role in the pathobiology of pancreatic cancer, inactivation of this putative tumor suppressor gene occurs more frequently in cell lines than in primary ductal pancreatic carcinomas.
|
8640773 |
1996 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No identifiable gene mutations were detected in any of the dysplasias or hyperplasias, while 2 (10%) deletions and 2 (10%) mutations of p16/CDKN2, along with 5 (25%) p53 mutations were found in the advanced carcinomas, yielding characteristic p16/ CDKN2 and p53 changes.
|
8835820 |
1996 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven of 9 alterations in p16/CDKN2 and p15/MTS2 were observed in serous (3 of 12), endometrioid (3 of 9) and clear-cell (1 of 4) carcinomas.
|
8980248 |
1996 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In contrast, only 1 of 10 (10%) colon carcinomas showed methylation of the 5' CpG island of p16/CDKN2.
|
7553622 |
1995 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast, in primary esophageal carcinomas, mutation frequency of the p16/CDKN2 gene has been controversial (0, 21, and 52% previously reported), and no reports are available for the mutation frequency of this gene in surgical specimens of gastric carcinomas.
|
7614482 |
1995 |